Dato-DXd trials for Lung cancer

All Dato-DXd trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Dato-DXd for Lung cancer

• A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
  NCT07535437 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
  NCT07098338 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 83 locations
• A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  NCT06417814 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female) · 303 locations
• Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
  NCT05061550 · Phase: Phase 2 · Ages: 18 Years to 95 Years · Sex: All (male and female) · 97 locations

Common questions

How many trials study Dato-DXd for Lung cancer?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.